Product References — Single Donor Human Complement Serum

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica

Posted by Leanne Kodsmann on

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica

Human Complement from Innovative Research was used in the following study:   Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica Tianjiao Duan, Alex J. Smith and Alan S. Verkman Journal of Neuroinflammation, October 2018 "... Specified concentrations of AQP4-IgG (or control human IgG, Thermo Fisher Scientific, Rockford, IL) and human complement (Innovative Research, Novi, MI) were added in Hank’s buffer, and cells were incubated at 37 °C for specified times. In some experiments, cells were exposed to serum of an AQP4-IgG seropositive NMO patient who met the revised diagnostic criteria for clinical disease. A fixable dead-cell stain (amine-reactive dye,...

Read more →

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Posted by Leanne Kodsmann on

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Human Complement Serum from Innovative Research was used in the following study:   Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga and Raymond L. Comenzo Experimental Hematology & Oncology, October 2018 "... Complement-rich human serum (CRHS) was from Innovative Research (Novi, MI), was aliquoted, cryopreserved and thawed for immediate use. For CDC studies, cells were aliquoted at 4 × 105 per well,...

Read more →

Human Complement Serum - May 31, 2017

Posted by Leanne Kodsman on

May 31, 2017 Innovative Research's Single Donor Human Complement Serum was recently used in the following study: Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis opticaLukmanee Tradtrantip, Xiaoming Yao, Tao Su, Alex J. Smith, Alan S. Verkman - Acta Neuropathologica, 2017 ... Complement dependent cytotoxicity Specified concentrations of AQP4-IgG (or control human IgG, Thermo Fisher Scientific, Rockford, IL) and human complement (Innovative Research, Novi, MI) were added in Hank's buffer, and cells were incubated at 37 °C for specified times. ...

Read more →

Single Donor Human Complement Serum Reference 4-22-15

Posted by Leanne Kodsman on

Innovative Research's Single Donor Human Complement Serum was recently used in the following study: An AntiC1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLAKA Thomas, NM Valenzuela, D Gjertson, A Mulder - American Journal of , 2015 Single donor normal human serum (NHS) was used as source of active complement (IPLA-CSERS; Innovative Research, Novi, MI). Monoclonal and polyclonal antibody sources. HLA-Ab came from two main sources...

Read more →

Pooled Complement Human Serum Reference 6-28-14

Posted by Leanne Kodsman on

Innovative Research's Pooled Complement Human Serum was recently used in the following study: Inhibitor (s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis opticaJ Ratelade, AS Verkman - Molecular Immunology, 2014We conclude that mice have limited utility as models of NMO. 2. Materials and methods. 2.1. Reagents and antibodies. Complement/sera from mouse (CD1 and C57BL/6 strains), rat (Wistar strain), guinea pig and human were purchased from Innovative Research (Novi, MI).

Read more →


×